OptiNose

Yahoo Finance • 2 days ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders

NEW YORK, March 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to sharehold... Full story

Yahoo Finance • 3 days ago

OPTN Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of OptiNose, to Paratek Pharmaceuticals

MONSEY, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of OptiNose, Inc. (Nasdaq: OPTN) (“OptiNose”) to Paratek Pharmaceuticals (“Paratek”) for $9.00 per sh... Full story

Yahoo Finance • 4 days ago

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings confere... Full story

Yahoo Finance • 4 days ago

Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)

Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient marketAcquisition advances Paratek’s vision to become a multi-product company foc... Full story

Yahoo Finance • 12 days ago

Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results

YARDLEY, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial result... Full story

Yahoo Finance • last year

Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference

YARDLEY, Pa., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will... Full story

Yahoo Finance • last year

Optinose Reports Third Quarter 2023 Financial Results and Operational Updates

Company reports third quarter 2023XHANCE net revenue of $19.8 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency as SG&A and R&D expenses decreased by $32M or 33% year-to-date PDUF... Full story

Yahoo Finance • last year

Optinose Announces Reporting Date for Third Quarter 2023 Financial Results

YARDLEY, Pa., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results... Full story

Yahoo Finance • 2 years ago

Optinose to Present at the 2023 Cantor Global Healthcare Conference

YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will... Full story

Yahoo Finance • 2 years ago

Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

YARDLEY, Pa., June 16, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted a non-... Full story

Yahoo Finance • 2 years ago

Optinose Reports First Quarter 2023 Financial Results and Operational Updates

Strong progress towards strategic objectives including acceptance of sNDA for review and prioritization of potential launch of XHANCE as first drug approved to treat chronic rhinosinusitis Company reports first quarter 2023XHANCE net reve... Full story

Yahoo Finance • 2 years ago

Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE

The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If approved, XHANCE is expected to be the... Full story

Yahoo Finance • 2 years ago

Optinose Announces Reporting Date for First Quarter 2023 Financial Results

YARDLEY, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results... Full story

Yahoo Finance • 2 years ago

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

YARDLEY, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted non-q... Full story

Yahoo Finance • 2 years ago

Optinose to Present at the Needham Virtual Healthcare Conference

YARDLEY, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will... Full story

Yahoo Finance • 2 years ago

Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

Company reports fourth quarter and full year 2022 XHANCE net revenue of $20.9 million and $76.3 million Company submitted sNDA for XHANCE label expansion in February 2023 Physicians diagnose chronic sinusitis 10 times more frequently tha... Full story

Yahoo Finance • 2 years ago

Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results

YARDLEY, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results... Full story

Yahoo Finance • 2 years ago

Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion

YARDLEY, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the submission of its supplemental new dr... Full story

Yahoo Finance • 2 years ago

Optinose Announces CEO Transition and Business Update

YARDLEY, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Peter Miller has stepped down as Chi... Full story

Yahoo Finance • 2 years ago

Optinose Appoints Paul Spence as Chief Commercial Officer

YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Paul Spence as Chief C... Full story